FP
AKBA icon

Foundry Partners’s Akebia Therapeutics AKBA Stock Holding History

Foundry Partners’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-64,512
Closed -$876K – 411
2020
Q2 		$876K Sell
64,512
-2,479
-4% -$25.6K 0.04% 314
2020
Q1 		$508K Sell
66,991
-23,643
-26% -$184K 0.03% 331
2019
Q4 		$573K Sell
90,634
-2,160
-2% -$10.3K 0.02% 339
2019
Q3 		$364K Sell
92,794
-218
-0.2% -$934 0.02% 363
2019
Q2 		$450K Sell
93,012
-270
-0.3% -$1.54K 0.02% 349
2019
Q1 		$764K Buy
93,282
+16,222
+21% +$111K 0.03% 329
2018
Q4 		$426K Sell
77,060
-130
-0.2% -$1.02K 0.02% 347
2018
Q3 		$682K Sell
77,190
-120
-0.2% -$1.07K 0.03% 341
2018
Q2 		$772K Buy
77,310
+22,569
+41% +$226K 0.03% 332
2018
Q1 		$522K Buy
+54,741
New +$766K 0.02% 346

Other funds holding AKBA

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Foundry Partners's AKBA Position: Q3 2020 in Review

Foundry Partners sold out of Akebia Therapeutics (AKBA) in Q3 2020, closing a stake of 64,512 shares — an estimated $876K sold.

Foundry Partners first reported a position in AKBA in Q1 2018 and held it in 10 quarters. The position peaked at $876K in Q2 2020. 164 funds tracked by Wall St. Rank hold AKBA as of Q3 2020.

  • Foundry Partners reported no remaining Akebia Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Foundry Partners sold 64,512 Akebia Therapeutics shares in Q3 2020, an estimated $876K.
  • Foundry Partners first reported a position in Akebia Therapeutics in Q1 2018 and held it in 10 quarters.
  • Foundry Partners's Akebia Therapeutics position peaked at $876K in Q2 2020.
  • 164 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2020.

Based on Foundry Partners's 13F filing for Q3 2020, filed 23 Oct 2020.